Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Sangamo Biosciences ( (SGMO) ) has provided an announcement.
On September 9, 2025, Prathyusha Duraibabu announced her resignation as Chief Financial Officer of Sangamo Therapeutics, effective October 1, 2025, to join a private AI company. Her departure is amicable and unrelated to any company disagreements. She will continue part-time to ensure continuity until a successor is appointed. The company acknowledges her significant contributions, particularly in strategic collaborations and investments, which have strengthened Sangamo’s position in the genomic medicines industry.
The most recent analyst rating on (SGMO) stock is a Hold with a $0.50 price target. To see the full list of analyst forecasts on Sangamo Biosciences stock, see the SGMO Stock Forecast page.
Spark’s Take on SGMO Stock
According to Spark, TipRanks’ AI Analyst, SGMO is a Neutral.
Sangamo Biosciences’ overall score is primarily impacted by its poor financial performance, which poses significant risks. While there are positive developments in clinical trials and strategic initiatives, these are overshadowed by financial instability and the need for additional funding.
To see Spark’s full report on SGMO stock, click here.
More about Sangamo Biosciences
Sangamo Therapeutics, Inc. operates in the biotechnology industry, focusing on neurology-focused genomic medicines. The company is known for its strategic collaborations and investment allocations in the genomic medicine space.
Average Trading Volume: 5,711,326
Technical Sentiment Signal: Sell
Current Market Cap: $160.4M
Learn more about SGMO stock on TipRanks’ Stock Analysis page.